查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1386383

登革熱疫苗市場報告：2030 年趨勢、預測與競爭分析

Dengue Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

登革熱疫苗趨勢與預測

預計到 2030 年，全球登革熱疫苗市場將達到 11 億美元，2024 年至 2030 年年複合成長率為 12.1%。該市場的主要促進因素是登革熱疫情日益嚴重以及全球疫苗開發的研發活動不斷增加。全球登革熱疫苗市場的未來看起來充滿希望，醫院、居家醫療和專科診所市場都有機遇。

登革熱疫苗市場洞察

Lucintel 預測，抗過敏藥物在預測期內將出現最高成長，因為它們被廣泛用於治療和預防過敏反應，例如登革熱疫苗接種後發生的過敏反應。

由於免疫接種等醫療保健服務的增加、人們對預防保健的興趣日益濃厚以及對更高品質醫療保健服務的需求，醫院將繼續成為市場中最大的細分市場。

由於政府為改善該地區的醫療基礎設施支出增加，預計亞太地區在預測期內將出現最高的成長。

本報告回答了 11 個關鍵問題：

  • Q.1. 細分市場中最有前途和高成長的機會是什麼？
  • Q.2.哪個細分市場將以更快的速度成長？為什麼？
  • Q.3.您認為哪些地區未來會出現更快的成長？為什麼？
  • Q.4. 影響市場動態的主要因素有哪些？市場的主要挑戰和商業風險是什麼？
  • Q.5. 這個市場的商業風險和競爭威脅是什麼？
  • Q.6.這個市場有哪些新趨勢？為什麼？
  • Q.7.市場客戶需求有何改變？
  • Q.8. 該市場有哪些新發展以及哪些公司處於領先地位？
  • Q.9.這個市場的主要企業有哪些？主要企業採取哪些策略配合措施來發展業務？
  • Q.10. 該市場上的競爭產品有哪些？由於材料或產品替代而導致市場佔有率下降的威脅有多大？
  • Q.11.過去年度發生了哪些併購事件，對產業產生了哪些影響？

目錄

第1章 執行摘要

第2章 全球登革熱疫苗市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球登革熱疫苗市場趨勢（2018-2023）與預測（2024-2030）
  • 按類型分類的全球登革熱疫苗市場
    • 減毒活病毒疫苗
    • 活病毒疫苗
    • 去活化疫苗
    • 亞單位疫苗
    • 核酸疫苗
  • 按治療分類的全球登革熱疫苗市場
    • 利尿劑
    • 抗過敏劑
    • 血液稀釋劑
    • 其他
  • 按配銷通路分類的全球登革熱疫苗市場
    • 醫院藥房
    • 線上藥房
    • 零售藥房
  • 全球登革熱疫苗市場（依最終用途）
    • 醫院
    • 居家護理
    • 專科診所
    • 其他

第4章 2018-2030年分地區市場趨勢及預測分析

  • 全球登革熱疫苗市場區域分佈
  • 北美登革熱疫苗市場
  • 歐洲登革熱疫苗市場
  • 亞太登革熱疫苗市場
  • 其他區域登革熱疫苗市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球登革熱疫苗市場成長機會（按類型）
    • 全球登革熱疫苗市場按治療方法的成長機會
    • 全球登革熱疫苗市場成長機會（按配銷通路）
    • 全球登革熱疫苗市場成長機會（依最終用途）
    • 全球登革熱疫苗市場成長機會（按地區）
  • 全球登革熱疫苗市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球登革熱疫苗市場產能
    • 全球登革熱疫苗市場的合併、收購和合資企業
    • 認證和許可

第7章 主要企業概況

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche
簡介目錄

Dengue Vaccine Trends and Forecast

The future of the global dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets. The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 12.1% from 2024 to 2030. The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

A more than 150-page report is developed to help in your business decisions.

Dengue Vaccine by Segment

The study includes a forecast for the global dengue vaccine by type, treatment, distribution channel, end use, and region.

Dengue Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Live Attenuated Vaccine
  • Chimeric Live Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine
  • Nucleic Acid Based Vaccine

Dengue Vaccine Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Diuretic
  • Anti-Allergic
  • Blood Thinners
  • Others

Dengue Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Dengue Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Dengue Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Dengue Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies dengue vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the dengue vaccine companies profiled in this report include-

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Dengue Vaccine Market Insights

Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Within this market, hospital will remain the largest segment due to increasing healthcare services including immunizations and growing focus towards preventative care and need for higher-quality healthcare services.

APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Features of the Global Dengue Vaccine Market

Market Size Estimates: Dengue vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Dengue vaccine market size by various segments, such as by type, treatment, distribution channel, end use, and region in terms of ($B).

Regional Analysis: Dengue vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, distribution channels, end uses, and regions for the dengue vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the dengue vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the dengue vaccine market size?

Answer: The global dengue vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for dengue vaccine market?

Answer: The global dengue vaccine market is expected to grow with a CAGR of 12.1% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the dengue vaccine market?

Answer: The major drivers for this market are escalating prevalence of dengue fever and rising R&D acitivities for vaccine development across the globe.

Q4. What are the major segments for dengue vaccine market?

Answer: The future of the dengue vaccine market looks promising with opportunities in the hospital, homecare, and specialty clinic markets.

Q5. Who are the key dengue vaccine market companies?

Answer: Some of the key dengue vaccine companies are as follows:

  • Mylan
  • BIO-MED
  • Teva Pharmaceutical
  • Sanofi
  • Novartis
  • GSK
  • F. Hoffmann-La Roche

Q6. Which dengue vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that anti-allergic is expected to witness highest growth over the forecast period due to its significant use to treat and prevent allergic reactions, such as those occur after a dengue vaccination.

Q7. In dengue vaccine market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period due to rising government expenditure for development of better healthcare infrastructures in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the dengue vaccine market by type (live attenuated vaccine, chimeric live attenuated vaccine, inactivated vaccine, subunit vaccine, and nucleic acid based vaccine), treatment (diuretic, anti-allergic, blood thinners, and others), distribution channel (hospital pharmacy, online pharmacy, and retail pharmacy), end use (hospitals, homecare, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Dengue Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Dengue Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Dengue Vaccine Market by Type
    • 3.3.1: Live Attenuated Vaccine
    • 3.3.2: Chimeric Live Attenuated Vaccine
    • 3.3.3: Inactivated Vaccine
    • 3.3.4: Subunit Vaccine
    • 3.3.5: Nucleic Acid Based Vaccine
  • 3.4: Global Dengue Vaccine Market by Treatment
    • 3.4.1: Diuretic
    • 3.4.2: Anti-Allergic
    • 3.4.3: Blood Thinners
    • 3.4.4: Others
  • 3.5: Global Dengue Vaccine Market by Distribution Channel
    • 3.5.1: Hospital Pharmacy
    • 3.5.2: Online Pharmacy
    • 3.5.3: Retail Pharmacy
  • 3.6: Global Dengue Vaccine Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Homecare
    • 3.6.3: Specialty Clinics
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Dengue Vaccine Market by Region
  • 4.2: North American Dengue Vaccine Market
    • 4.2.1: North American Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.2.2: North American Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.3: European Dengue Vaccine Market
    • 4.3.1: European Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.3.2: European Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.4: APAC Dengue Vaccine Market
    • 4.4.1: APAC Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.4.2: APAC Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others
  • 4.5: ROW Dengue Vaccine Market
    • 4.5.1: ROW Dengue Vaccine Market by Treatment: Diuretic, Anti-Allergic, Blood Thinners, and Others
    • 4.5.2: ROW Dengue Vaccine Market by End Use: Hospitals, Homecare, Specialty Clinics, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Dengue Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Dengue Vaccine Market by Treatment
    • 6.1.3: Growth Opportunities for the Global Dengue Vaccine Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Dengue Vaccine Market by End Use
    • 6.1.5: Growth Opportunities for the Global Dengue Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Dengue Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Dengue Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Dengue Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Mylan
  • 7.2: BIO-MED
  • 7.3: Teva Pharmaceutical
  • 7.4: Sanofi
  • 7.5: Novartis
  • 7.6: GSK
  • 7.7: F. Hoffmann-La Roche